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Abstract
Haematopoietic cell number is maintained by a delicate balance between cell proliferation,
differentiation and death. Gene knockout studies in mice have revealed the complex roles of
cyclins, CDKs, and CDK inhibitors in regulating cell proliferation and differentiation in the
haematopoietic system. These studies point to families of cell cycle regulators which display both
redundant and unique roles within a lineage and developmental-stage specific manner. Moreover,
the promiscuity of these cell cycle regulators is critical for haematopoietic cell proliferation and
differentiation. In this review, we discuss the current evidence from mouse models that the
complexity and multifarious nature of the haematopoietic system is critical for its form and
function.
Background
In complex, multi-cellular organisms, the interplay
between cell proliferation, differentiation, and death
determines cell number, tissue architecture and function.
This dynamic equilibrium is best appreciated in tissues
with high volumes of cell turnover, in particular the hae-
matopoietic system [1,2]. The human haematopoietic sys-
tem turns over approximately 1011 blood cells everyday,
and the daily loss of blood cells must be balanced by an
equally high rate of cell proliferation. Moreover, prolifer-
ation must be coupled with cell differentiation to contin-
uously reconstitute and replenish all different cell lineages
of the haematopoietic system. In addition to this routine
turnover, the haematopoietic system exhibits remarkable
flexibility at times of physiological stress. For example, red
blood cell numbers increase under conditions of hypoxia,
while granulocyte, macrophage and lymphocyte popula-
tions expand during infection. In contrast, the uncon-
trolled proliferation of haematopoietic stem cells (HSC)
and progenitors is symptomatic of hyperplastic diseases
and leukaemia. Thus, despite the ability of haematopoi-
etic cells to undergo rapid proliferation and differentia-
tion entry into the cell cycle is under stringent control
during haematopoietic cell development; preventing pro-
genitor populations becoming exhausted as a result of
continuous division by restricting entry into the cell cycle.
Indeed, the optimal reconstitution of haematopoiesis is
achieved by quiescent cells [3], whereas cells which have
already entered the latter stages of the cell cycle are inef-
fective at engraftment [4]. Evidence from murine and pri-
mate studies also suggests that a pool of slowly cycling
HSC may also exist [5-7]. Ultimately, the decision to pro-
liferate or remain in a quiescent state is central to both the
maintenance and immunological function of the haemat-
opoietic system, and is a decision largely executed by cell
cycle regulation.
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Table 1: A summary of phenotypes observed following deletion of cell cycle regulating genes
Gene 
deletion
Expression in haematopoieitc system Haematopoietic system Other phenotypes
Cyclin D1 Unexpressed in the majority of haematopoietic lineages No overt haematopoietic phenotype Developmental neurological abnormalities; hypoplastic 
retina; impaired Schwann cell regeneration
Cyclin D2 Expression in majority of haematopoietic cell types; absent in 
small pre-B cells
Abnormal B-lymphocytes: impaired proliferation; hypo-
responsive to BCR and mitogenic stimulation; impaired 
CD5 B cell development; immunodeficiency in IgG3 and 
IgA
Sterility in females, cerebellar abnormalities, hypoplastic 
testes in males; cerebellar abnoralities; reduced 
susceptability to specifc cancers
Cyclin D3 Expression in majority of haematopoietic cell types Depletion of small pre-B cells; impaired thymic T cell 
development; impaired maturation of granulocytes in 
the bone marrow; reduced levels of circulating 
neutrophil granulocytes
Resistant to Notch-driven leukaemias
Cyclin D2; 
Cyclin D3
Upregulation of cyclin D3 in cyclin D2 null B cells; ubiquitous 
upregulaion of wild-type cyclin in single deletion embryos
As single deletions with severe megaloblastic anemia Embryonic lethal at late developmental stages
CDK2 Expression in majority of haematopoietic cell types No overt haematopoietic phenotype Reduced body size; infertility
CDK4 Expression in majority of haematopoietic cell types No overt haematopoietic phenotype Dwarfism-like phenotype; infertility; hypocellularity in 
many organs; diabetes
CDK6 Expression in majority of haematopoietic cell types Mild haematopoietic defects: hypoplasia of thymuses 
and spleens; delayed G1 progression in lymphocytes; 
depletion of megakaryocytes and erythrocytes
No overt phenotype
CDK2; 
CDK4
As above Severe haematopoietic defects: reduced proliferation of 
multipotential progenitors; decrease in cellularity of all 
haematopoietic subpopulations
Embryonic lethality due to heart defects
CDK4; 
CDK6
As above Multi-lineage haematopoietic abnormalities: reduction 
in cellularity of lymphoid, myeloid and granulocyte-
macrophage progenitors; loss of mature 
haematopoietic cells
Late-stage embryonic lethal; anaemia
p15INK4b Absent in HSC; increases in myeloid and lymphoid lineages No overt haematopoietic phenotype No overt phenotype
p16INK4a Highly expressed in HSC; down-regulated with differentiation of 
all lineages
No overt haematopoietic phenotype; increased ability 
for clonal expansion of haematopoetic progenitor cells; 
long latency B-cell lymphomas
No overt phenotype
p18INK4c Higher levels in HSC compared with more mature myeloid and 
lymphoid cells
Hyperplastic spleen and thymus; increased cellularity 
and hypersensitivity of T and B-cell lymphocytes to 
mitogenic stimulation; T-cell lymphoma
Widespread hyperplasia and organomegaly
p19INK4d Higher levels in HSC compared with more mature myeloid and 
lymphoid cells
No overt haematopoietic phenotype No overt phenotype
p21Cip1 Variable Increase in HSC cycling; reduced progenitor cell 
replication; decrease of circulating inflammatory 
monocytes in peripheral blood
No overt phenotype
p27Kip1 Variable Increased progenitor cell activity; hyperplasia observed 
in most haematopoietic organs, particularly 
pronounced in the thymus and spleen
Multiple organ hyperplasia
p57Kip2 Induced by TGF-β in specific progenitor/HSC (CB-CD34) No overt haematopoietic phenotype No overt phenotype
HSC; haematopoeitic stem cells, CDK; cyclin-dependent kinase.
Cell Division 2007, 2:6 http://www.celldiv.com/content/2/1/6The cell cycle: G1/S phase transition
Cell proliferation requires entry into and successful pro-
gression through the cell division cycle [8,9]. The mam-
malian cell cycle can be divided into four phases wherein
S phase (DNA-synthesis) and M phase (mitosis) are sepa-
rated by two intervals, G1 (gap 1-between M and S) and
G2 (gap 2-between S and M). Nevertheless, most cells are
in a quiescent or resting phase termed G0. The transition
through G1 into S phase of the cell cycle represents a crit-
ical period within which cells become committed to cell
cycle progression versus growth arrest, becoming inde-
pendent of growth factor stimuli, and as such is of partic-
ular importance to the haematopoietic system.
G1/S-phase stage transition is regulated by two families of
G1 cyclins, the D-type cyclins (cyclin D1, D2, and D3)
and the E-type cyclins (cyclin E1 and E2) [8] and their
dependent kinases (CDK4, -6 and -2). CDK4 and CDK6,
bind to and are activated by the D-type cyclins, while
CDK2 activity is induced by the E-type cyclins [9]. The
activities of the CDKs are regulated by two families of cyc-
lin dependent kinase inhibitors (CKIs) the Cip/Kip family
and the INK4 family. The Cip/Kip family, comprised of
p21Cip1, p27Kip1 and p57Kip2 modulate the activities of cyc-
lin D-, E- and A-dependent kinases (reviewed in [8]). The
INK4 family, comprised of p15INK4b, p16INK4a, p18INK4c,
and p19INK4d specifically inhibit D-type cyclin associated
CDK4 and CDK6 activity by formation of binary com-
plexes which block active cyclin-CDK complex formation.
The anti-proliferative activity of INK4 proteins is also in
part due to competition with Cip/Kip proteins for binding
to the D-type cyclin/CDK complex, releasing the Cip/Kip
proteins to inhibit cyclin E-CDK2. Upon activation cyclin
D-CDK4/6 and cyclin E-CDK2 kinases phosphorylate
members of the retinoblastoma (Rb) protein family, pRb,
p107, and p130 early and late in G1 respectively leading
to the dissociation of Rb and E2F. The release of pRb-
related proteins from E2F repression induces progression
from G1 to S phase.
In single cell organisms, such as yeast, one cyclin depend-
ent kinase (CDK) is enough to mediate cell cycle progres-
sion. However, concomitant with the increased levels of
complexity and control required in multicellular organ-
isms, mammalian cells have evolved families of cell cycle
regulators, including multiple CDKs, cyclins, and CDK
inhibitors (CKIs). The perceived rational for having mul-
tiple families of cell cycle regulators is that redundancy
enables compensation where a family member becomes
deregulated. However, differential expression patterns
and activities of multiple family members may also allow
for an increase in functional complexity, independent of
their roles as guardians against pathway deregulation.
Analysis of mice deficient of cell cycle regulators has pro-
vided evidence that cell cycle regulators exhibit both
redundancy and specificity in vivo dependent on cell line-
age and developmental timing. Moreover, studies on sin-
gle as well as combined gene deletion mice have
confirmed the overlapping functions of cell cycle regula-
tors in haematopoietic cell proliferation and develop-
ment, and demonstrated that the loss of function of a cell
cycle regulator can be compensated by another family
member (see Table 1). However, these studies have also
revealed that some cell cycle regulators have unique roles,
which cannot be substituted by other family members
during haematopoiesis. Examples of single and double-
deletion mutants generated in mice, and the cell type
affected are shown in Figure 1. In the forthcoming review
we summarize the evidence that D-type cyclins, CDKS and
CKIs exhibit redundant, unique, and promiscuous roles in
haematopoiesis.
D-type cyclins
The D-type cyclins are the first components of the cell
cycle machinery to become induced in response to
mitogen stimulation, and provide a link between the
extracellular mitogenic environment and the cell cycle.
Two of the three D-type cyclins are usually expressed in
every mammalian cell type, and the presence of multiple
D-type cyclins is suggestive of functional redundancy.
Indeed, the ablation of all D-type cyclins does not result
in apparent defects in most other cell types and tissues
until late in embryonic development (E17.5) where anae-
Gene deletions affecting haematopoiesisFigure 1
Gene deletions affecting haematopoiesis. Gene dele-
tions are shown next to the cell type/pathway affected. The 
arrow indicates whether gene deletion results in an increase 
in cell number/activity/maturation or a decrease in cell 
number/activity/maturation. HSC, haematopoeitic stem cells; 
CMP, common myleoid progenitor; CLP, common lymphoid 
progenitor; MEP, megarkaryocyte/erythroid progenitor; 
GMP, granulocyte-macrocyte progenitor; CDK; cyclin-
dependent kinase.Page 3 of 9
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doxically, mouse deletion experiments have established
that whilst loss of one or two of the D-type cyclins has lit-
tle effect on the development of the haematopoietic sys-
tem, simultaneous deletion of all D-type cyclins
completely suppresses haematopoiesis, and prevents the
expansion of haematopoietic stem cells [10]. These stud-
ies suggest that the inability of other cyclin-CDK kinase
complexes to compensate for the loss of cyclin D activity
is unique to the haematopoietic system. However,
although these studies have established the overall impor-
tance of the D-type cyclin family in haematopoiesis, the
specific roles of individual D-type cyclins are only begin-
ning to emerge.
Cyclin D1
Cyclin D1 is not normally expressed in the majority of
haematopoietic lineages, despite its collaborative role in
haematopoietic stem cell expansion [10]. However, cyclin
D1 expression has been detected in B-cell malignancies. In
contrast, cyclin D2 and D3 co-express in a large number of
haematopoietic cell types and are implicated in the prolif-
eration and differentiation of most haematopoietic cells.
Consistent with this hypothesis both cyclin D2 and D3
are essential for haematopoietic cell proliferation. How-
ever, cyclin D2 or D3 null mice do not demonstrate overt
haematopoietic defects probably due to the fact that com-
pensation exists between these two D-type cyclins.
Cyclin D2
Detailed analysis of different haematopoietic compart-
ments has revealed unique tissue-specific roles for cyclin
D2 in antigen-dependent B cell clonal expansion and
CD5 B cell development. For example, B cells from cyclin
D2-/- mice demonstrate a specific requirement for cyclin
D2 in B cell receptor(BCR)-induced proliferation [11,12].
Moreover, although conventional(B2) B cell development
proceeds normally in cyclin D2 null mice, mature B cells
in the spleens are hypo-responsive to BCR and mitogenic
stimulation, and enter the cell cycle at a slower rate when
compared with their normal counterparts in response to
BCR stimulation [13]. Cyclin D2 is also important in
CD5+(B1) B cell development; the CD5+ B cell compart-
ment in the peritoneal cavity is dramatically reduced in
cyclin D2 deficient mice [13]. Cyclin D2 deficient mice
also exhibited fewer B cell progenitors (Sca1+B220+) but
normal levels of other haematopoietic progenitor cells
[14]. In addition, clonal assays demonstrated that colo-
nies from cyclin D2 null mice were less mature (CD19lo)
than those from wild-type mice (CD19hi) indicating that
cyclin D2 is rate-limiting for the production of B lym-
phoid progenitor cells whose proliferation does not
depend on BCR signaling. Normal CD5+B cells are impor-
tant for eliminating bacterial pathogens through secretion
of IgG3 subtype antibodies, and functioning as precursors
of IgA-secreting plasma cells. Thus, cyclin D2 null mice
may be expected to be deficient in host defense against
bacterial pathogens; indeed, cyclin D2-/- mice display spe-
cific immunodeficiency in IgG3 as well as in IgA levels.
Cyclin D3
Cyclin D3 also has a unique role in B cell development.
Analysis of cyclin D3 null mice showed that cyclin D3 was
specifically required for the development of pre-B cells
[15]. Consistent with this, cyclin D3, but not cyclin D2, is
induced during the transition from pro-B cell to pre-B cell.
Although in normal mice cyclin D2 is abundantly
expressed in pro-B cells (CD43+B220+CD25-), large pre-B
cells (CD43loB220+CD25lo), and immature cells
(B220+IgM+) from the bone marrow, it is absent in small
pre-B cells (CD43-B220+CD25+). Indeed, cyclin D3 is the
only D-type cyclin expressed in these small pre-B cells,
and consequently small pre-B cells are depleted in cyclin
D3 deficient mice.
Cyclin D3 also has a specific role in T cell development.
Cyclin D3 deficient mice display a defect in thymic T cell
development characterized by a significant decrease in
CD4+CD8+ double-positive (DP) T cells. This phenotype
results from a non-redundant role for cyclin D3 in the
maturation of CD4-CD8- double-negative (DN) T cells,
which are the precursors of DP T cells. In normal mice,
developing DN T cells successively pass through four
stages (DN-1 to DN-4), whereas cyclin D3 deficient thy-
mocytes fail to undergo the proliferative burst that nor-
mally occurs during the DN-3 to DN-4 transition. In
addition, cyclin D3 null mice also display defects in the
maturation of granulocytes in the bone marrow and have
reduced levels of circulating neutrophil granulocytes [16].
As a result, cyclin D3 null mice are unable to mount a nor-
mal response to bacterial infection. Yet, the development
of the myeloid progenitors proceeds relatively normally in
mice lacking cyclin D3, indicating that the cyclin D3 func-
tion is only required at later stages of neutrophil develop-
ment.
Compensation and redundancy of cyclin D2 and D3
Together these studies demonstrate the importance of cyc-
lin D2 and cyclin D3 in haematopoiesis. However, some
questions remain unanswered; namely, cyclin D2 is essen-
tial for B cell development, yet why do cyclin D2 null mice
have a normal number of conventional (B1) B cells? In
fact, induction of cyclin D3 in cyclin D2 null mice has
been found to compensate for loss of cyclin D2, and allow
for the development of a normal number of mature B-
lymphocytes [11]. In normal mature B cells cyclin D2 is
the predominant D-type cyclin and cyclin D3 is not
expressed at significant levels. However, in cyclin D2 null
B cells, cyclin D3 is up-regulated to compensate for the
loss of cyclin D2, and has been shown to complex withPage 4 of 9
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onstration that loss of a D-type cyclin causes specific
expression and functional compensation by another
member of the family in vivo, and thus provides a ration-
ale for the presence of mature B-lymphocytes in cyclin D2-
/- mice [11,14].
The compensation between different D-cyclins was fur-
ther confirmed by double D-type cyclin deletion experi-
ments, generating mice expressing only one cyclin D.
These studies revealed that in single-cyclin D embryos, the
tissue-specific expression patterns of D-cyclins were lost
and the remaining D-cyclin was ubiquitously expressed
[10]. These double D-type cyclin deleted mice did not
show additional haematopoietic phenotypes compared
with the single D-type cyclin deficient mice, except that
cyclin D2 and -D3 deletion is embryonic lethal at late
developmental stages (~E18.5), and cyclin D2 and -D3
null embryos developed severe megaloblastic anaemia
[10].
Cyclin-dependent kinases (CDKs)
CDK4 and -6 are the preferred catalytic subunits of cyclin
D. Mice lacking the CDK4 gene display a dwarfism-like
phenotype, infertility, and hypocellularity in many organs
(see Table 1). However, no overt haematopoietic pheno-
type is observed in the CDK4-deficient mice, probably
reflecting the compensation for loss of CDK4 by CDK6
[17]. In contrast, CDK6 null mice exhibit mild haemat-
opoietic defects, including hypoplasia of thymuses and
spleens, and depletion of megakaryocytes and erythro-
cytes [18]. Thus, it appears that CDK6 has a developmen-
tal and proliferative role specific for haematopoietic cells.
Consistent with this notion, deletion of CDK6 results in
delayed G1 progression in lymphocytes, but not in other
cell types, such as mouse embryo fibroblasts.
Interestingly, mice defective for both CDK4 and CDK6
have a similar but milder phenotype compared with D-
type cyclin deficient mice. CDK4 and -6 double mutant
mice also display multi-lineage haematopoietic abnor-
malities, including a reduction in cellularity of lymphoid,
myeloid and granulocyte-macrophage progenitors as well
as a significant decrease in number of the more mature
haematopoietic cells, such as monocytes, macrophage,
lymphocytes and erythrocytes. Interestingly, further stud-
ies have revealed that D-type cyclins complex with CDK2
in the absence of CDK4 and -6, which may account for the
less severe haematopoietic phenotype observed in cyclin-
D null mice versus CDK4 and -6 null mice.
CDK2 is activated by E-type and A-type cyclins, and its
activity is required for the transition through the G1/S and
S phases. Unexpectedly, analysis of CDK2 deficient mice
showed that CDK2 is dispensable for mouse develop-
ment, suggesting functional compensation between dif-
ferent CDKs [19]. Although the CDK2-/- mice have
reduced body sizes, CDK2 null mice do not display any
haematopoietic specific defects. However, consistent with
the compensation for CDK4 by CDK2, double deletions
of CDK4 and CDK2 results in the reduced proliferation of
multipotential progenitors, culminating in a decrease in
cellularity in all haematopoietic subpopulations [20].
These findings indicate that CDK4, not only has overlap-
ping roles with CDK6, but that in the absence of CDK4,
cyclin D may cooperate with CDK2 to control haemat-
opoietic progenitor proliferation. Moreover, it suggests
that only regulators for early G1, but not later cell cycle
phases have unique roles for haematopoietic develop-
ment. Indeed, mice null for E-type cyclins demonstrate
largely normal development but severely impaired
endoreplication of trophoblast giant cells and megakary-
ocytes; thought largely to reflect a failure to incorporate
MCM helicase into DNA replication origins during G1/S
phase progression [21,22]. However, whilst cyclin A1/2,
cyclin B1/2/3 and cdc2(CDK1) are important cell cycle
regulators for G2 and M phase progression, single gene
deletion mice for these cell cycle regulators have no obvi-
ous haematopoietic phenotypes.
The Cip/Kip family of CKIs
The Cip/Kip family of proteins are potent inhibitors of
CDK2 kinases and may also stabilize cyclin D-CDK4/-6
complex formation. Despite p57Kip2 being previously
reported to be induced by transforming growth factor β
(TGF-β) in primary human CD34+ umbilical cord blood
progenitor/stem cells (CB-CD34) [23], p21Cip1 and
p27Kip1 are the predominant CKIs expressed in haemat-
opoietic cells (see Table 1).
It is generally believed that p21Cip1 and p27Kip1 set the sto-
ichiometric thresholds for cell cycle entry and progression
through G1 in response to mitogenic stimuli, such as
cytokines and interactions with stromal cells and the
Examples of cell cycle regulators exhibiting specificity, com-pensation, and redundancy during haematopoiesisFigure 2
Examples of cell cycle regulators exhibiting specifi-
city, compensation, and redundancy during haemat-
opoiesis. Genes demonstrating specificity, compensation, 
and redundancy are shown with consequences for haemat-
opoiesis.Page 5 of 9
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p21Cip1 and p27Kip1 are critical regulators of the increased
HSC-specific entry into the cell cycle observed in FoxO
deficient mice [24,25], implicating p21Cip1 and p27Kip1 in
maintenance of HSC quiescence. Interestingly, phos-
phatase and tensin homologue (PTEN), which functions
as a negative regulator of the phosphatidylinositol-3-OH
kinase (PI(3)K)-Akt pathway, a known negative regulator
of FOXO, may also restrict HSC activation [26].
Experimental evidence from p21Cip1 and p27Kip1 deficient
mice suggests that p21Cip1 and p27Kip1 have specific roles
in the regulation of quiescence of HSC and progenitors,
respectively. For instance, p21Cip1 knockout mice exhibit
an increase in HSC cycling and exhaustion upon trans-
plantation, supporting a role for p21Cip1 in stem cell qui-
escence. Furthermore, p21Cip1 may promote DNA repair,
thereby maintaining stem cell integrity. In contrast,
p27Kip1 knockout mice display increased progenitor cell
activity, and evidence suggests that whilst p27Kip1 controls
progenitor cell replication, it does not control HSC pool
size [27,28]. Paradoxically, haematopoietic progenitor
cells express p21Cip1 at a high level, and although p21Cip1
maybe sequestered from CDK2 in these cells, p21Cip1 null
mice display reduced progenitor cell replication, suggest-
ing p21Cip1 expression is required for progenitor cell repli-
cation. Interestingly, both the p21Cip1 and p27Kip1 deleted
mice retain multi-lineage haematopoietic differentiation
potential [29]. The mechanisms by which p21Cip1 and
p27Kip1 gene inactivation differentially affects HSC and
progenitors are not clearly understood. One possibility is
that p21Cip1 specifically binds and regulates cellular mole-
cules through domains that are not found in p27Kip1 and
vice versa. Indeed, p21Cip1 and p27Kip1 differ substantially
at their carboxy-terminus, and it is possible that domains
located at this region confer specific functions [8].
Although the paradigm for Cip/Kip activity is to prevent
cell cycle progression through inhibiting the CDK2 kinase
activity, recent evidence demonstrated that CDK2 is dis-
pensable for cell cycle inhibition mediated by the CKIs
p27Kip1 and p21Cip1 as the loss of p27Kip1 and p21Cip1 con-
fers similar proliferative advantages to cells with or with-
out CDK2 [30]. These data suggests that either p27Kip1 or
p21Cip1 have CDK2-independent cell cycle functions, or
cells possess compensatory mechanisms that efficiently
bypass their requirement for CDK2.
Aside from a decrease in HSC renewal capacity, mice lack-
ing p21Cip1 have no significant haematopoietic defects,
except that they have a substantial decrease in inflamma-
tory circulating monocytes in peripheral blood [31]. In
contrast, mice lacking p27Kip1 display multiple organ
hyperplasia, with the most pronounced hyperplasia
observed in the haematopoietic organs, such as thymus
and spleen. Thymic hyperplasia in p27Kip1 null mice was
associated with increased T lymphocyte proliferation as a
result of decrease in growth factor dependency. In the
spleen, the absence of p27Kip1 selectively enhanced prolif-
eration of haematopoietic progenitor cells. Ex vivo prolif-
erative assays also demonstrated that T and B lymphocytes
lacking p27Kip1 are hypersensitive to antigen receptor and/
or mitogen stimulation. Thus, p27Kip1 deficiency may
cause an enhanced proliferation in response to mitogens
in progenitors and more mature haematopoietic cells [32-
34].
The INK4 family of CKIs
The INK4 family have an essential role in G1 cell cycle
phase progression through specifically inhibiting cyclin
D-CDK4/6 kinase activity.
p16INK4a is highly expressed in HSC, and down-regulated
with differentiation of all lineages [35]. Loss of p16INK4A
in vitro increases the growth rate of myeloid colonies, and
confers an increased ability for clonal expansion of ham-
atopoetic progenitor cells [36]. However, while it influ-
ences the growth and self-renewal kinetics of
haematopoietic stem cells, p16INK4a deficient mice do not
exhibit abnormal haematopoiesis [37], suggesting its role
in blood cell differentiation is not essential. Mice lacking
p16INK4a are not predisposed to cancer, except for a small
percentage of animals that develop B-cell lymphomas
after a long latency [38,39]. Furthermore, whilst p16INK4a
homozygous mutations are observed in 35% of acute
lymphoblastic leukaemia (ALL) patients, p16INK4a dele-
tion is not an independent prognostic factor in ALL [40].
In contrast, p15INK4b is absent in HSC, and its level
increases in myeloid and lymphoid lineages [35,41].
Although hypermethylation of the p15INK4b gene pro-
moter region is a common event in acute myeloid leukae-
mia, transformation of myeloid cells by deregulated c-
Myc is not thought to require inactivation of p15INK4b
[42]. However, as p15INK4b is regulated by TGF-β1, which
may maintain HSC quiescence independently of p21Cip1
or p27Kip1 [43], the role of p15INK4b in stem cell fate
requires further investigation. Interestingly, p15INK4b null
mice do not display gross developmental defects, except
for extramedullary haematopoiesis and lymphoid hyper-
plasia in spleen and lymph nodes [44], suggesting that
p15INK4b has specific roles in regulating the proliferation
of more mature haematopoietic cells.
p18INK4c and p19INK4d are expressed at higher levels in
HSC compared with more mature myeloid and lymphoid
cells [45]. In addition, the G1 arrest necessary for the ter-
minal differentiation of B lymphocytes to immunoglobu-
lin secreting plasma cells requires p18INK4c [45-47]. In
contrast, mice lacking p19INK4d show normal haematopoi-Page 6 of 9
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ferentiate normally [48]. Predictably, mice lacking
p18INK4c develop widespread hyperplasia and organomeg-
aly similar to those developed by p27Kip1 deficient mice
demonstrating lymphoproliferative disorders and T cell
lymphomas [44,49]. In addition, p18INK4 deleted mice
exhibit disproportionately enlarged and hyperplastic
spleen and thymus. Although T and B lymphocytes
develop normally in p18INK4c deficient mice, they both
exhibit increased cellularity and hypersensitivity to
mitogenic stimulation.
Despite p15INK4b and p18INK4c single gene deletion mice
having similar haematopoietic phenotypes, combined
deletion of p15INK4b and p18INK4c does not result in a more
severe phenotype, suggesting that p15INK4b and p18INK4c
may function in different haematopoietic cell types and
have cell-type specific functions [44]. Loss of p18INK4c in T
cells leads to hyperproliferation in response to T cell
receptor (TCR) and/or co-receptor stimulation. These data
suggest a model in which p18INK4c functions as an inhibi-
tory threshold in quiescent T cells and modulates prolifer-
ation of T cells [50]. Interestingly, p18INK4c deleted HSC
retain multilineage differentiation potential and are pro-
tected from exhaustion caused by p21Cip1 deficiency,
likely by a counteracting mechanism against cellular
senescence, indicating that p18INK4C has a role in restrict-
ing cell cycle entry and thus the pool size of HSC [51,52].
Cooperation between Cip/Kip family of CKI and pRb-
related proteins
Recent combined gene knock-out experiments have
alluded to promiscuous roles of cell cycle regulators dur-
ing haematopoiesis. The lack of overt proliferative pheno-
types in the major haematopoietic organs of the p27Kip1-/-
mice indicates functional redundancy and compensation
exists to prevent excess uncontrolled proliferation.
Indeed, analysis of p27Kip1 and p130 deficient mice have
revealed that the pRb-related protein p130 can cooperate
with p27Kip1 to regulate the proliferation of a number of
haematopoietic lineages [53].
In p27Kip1 and p130 double deficient mice, the cellularity
of the spleens but not the thymuses is significantly
increased compared with their p27Kip1-/- counterparts,
affecting the lymphoid, erythroid and myeloid compart-
ments [53]. In particular, in vivo cell proliferation is signif-
icantly augmented in the B and T cells, monocytes,
macrophages and erythroid progenitors suggesting that
p130 can compensate in part for the loss of p27Kip1. In
fact, analysis of p27Kip1 deficient splenocytes has shown
that p130 can function as a CDK2 inhibitor and can com-
pensate for the loss of p27Kip1. However, p130 and p27Kip1
double deficient thymocytes still lack a significant prolif-
erative phenotype. This observation may be in part
explained by the report that p107, like p130, can also
interact with CDK2 in the spleen and thymus of p27Kip1
null mice, suggesting that p107 may also be able to com-
pensate for the absence of p27Kip1 to modulate CDK2
activity. Interestingly, in the thymus the amount of p107
binding to CDK2 increases when p27Kip1 is absent, sug-
gesting that competitive binding of p107 and p27Kip1 to
CDK2 may exist.
Thus, this compensatory mechanism can help to explain
the lack of a significant proliferative phenotype in the
p130 and p27Kip1 double deficient thymocytes and possi-
bly, for the absence of even more severe disorders in the
splenocytes. Moreover, in the thymocytes, the expression
level of p107 is high when compared with the spleno-
cytes, thus allowing p107 to play a more prominent role
than p130 in inhibiting CDK2 activity. Consequently, the
lack of excessive thymocyte proliferation when both p130
and p27Kip1 are lost may represent the high levels of p107
associated with CDK2 in the thymus but not the spleen
[53]. It also appears that the relative levels of p107 or
p130 expression in a specific tissue type dictates which of
the pRb-related proteins cooperate with p27Kip1 to regu-
late cell cycle entry and progression. This compensatory
mechanism may provide an essential proliferation control
in settings where p27Kip1 is not expressed at normal levels,
as is the case in many human tumours and hyperplastic
conditions.
Conclusion
It is now evident that the haematopoietic system displays
a unique and specific dependency for cell cycle regulators,
which is not unexpected, given the critical role of prolifer-
ation and differentiation in haematopoiesis. Furthermore,
the cell cycle proteins involved in haematopoiesis almost
exclusively regulate G1 entry and transition, probably
attributable to the fact that the decision for cells to con-
tinue with cell cycle progression or to differentiate is often
made in G1 phase [54]. A striking observation from
mouse deletion experiments is that cell cycle regulators
can exhibit specific, redundant, and compensatory activi-
ties, often, but not exclusively, linked to their temporal
expression patterns during haematopoietic development
(Figure 2).
Indeed, the lack of overt haematopoietic defects in the sin-
gle and multiple cell cycle regulator gene deficient mice
reveals that compensation and functional redundancy
exist between members of individual cell cycle regulator
family. In most circumstances, the masked phenotypes are
results of the expression of more than one family member
in a particular cell type. However, in some unique situa-
tions, the loss or deregulation of a cell cycle regulator
leads to the compensatory induction of another familyPage 7 of 9
(page number not for citation purposes)
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D2 by cyclin D3 in B cells described previously.
Evidence from the single and multiple gene deficient
mouse studies also reveals specific non-overlapping roles
for distinct cell cycle regulators such as p21Cip1, p27Kip1,
and cyclin D2 during haematopoiesis. However, the
majority of the present evidence has pointed to the tissue-
specific expression patterns rather than specialised func-
tions of cell cycle regulators as the basis for their cell type
specific roles. For example, the specific requirement of
cyclin D3 for pre-B cells is due to the fact that only cyclin
D3 is expressed in these cells, and in addition, cyclin D2
can substitute for most functions of cyclin D1 in mice
knock-in experiments [55]. However, in the case of
p21Cip1 and p27Kip1, their ability to regulate the self-
renewal capacity and pool sizes of haematopoietic stem
cells and progenitors, respectively, cannot be attributable
to their cell type specific expression, as both are expressed
in haematopoietic stem cells [1], and may reflect differen-
tial binding-specificities [8].
Most recent studies also reveal unexpected compensatory
mechanisms, where the loss of one cell cycle regulator can
be compensated by members of another family. For exam-
ple, p130(RB2) has been shown to be able to substitute
for the absence of p27Kip1. The fact that the haematopoi-
etic phenotype in p130RB2 and p27Kip1 double mutant
mice is stronger than that in p130RB2 or p27Kip1-null mice
indicates that their contribution to the phenotypes
observed in p130RB2 and p27Kip1 double mutant mice is
additive rather than a complete functional redundancy.
Ultimately, cell cycle regulators cooperate to set thresh-
olds for cell cycle entry and exit in different lineages and
cell types although there can be no doubt that functional
redundancies between family members can protect cells
from the consequence of deregulated cell cycle regulators.
Redundancy may also serve to generate extra layers of con-
trol and complexity, which is required in multiorganisms.
This allows specific developmental and proliferative clues
to be channelled to distinct tissues and cells. In fact, the
unique expression patterns and specific functions of these
cell cycle regulators has provided specific functions for cell
cycle regulators in haematopoiesis.
Intriguingly, most of the specific haematopoietic pheno-
types only come to prominence after more detailed re-
examination of the gene-deletion mice. As a consequence
further evidence for specific and redundant roles of the
cell cycle regulators in haematopoiesis is likely to be dis-
covered. This information will provide crucial insights for
devising new therapeutic strategies against the broad
range of haematopoietic diseases.
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